Recent findings indicate that microRNAs (miRNAs) are critical for the regulatory network of adipogenesis in human mesenchymal stem/stromal cells (MSCs). Fetal MSCs derived from amniotic fluid (AF-MSCs) represent a population of multipotent stem cells characterized by a wide range of differentiation properties that can be applied in cell-based therapies. In this study, miRNA microarray analysis was performed to assess miRNA expression in terminal differentiated AF-MSCs into adipocyte-like cells (AL cells). MiR-26a was identified in high expression levels in AL cells indicating a critical role in the process of adipogenesis. Overexpression of miR-26a in AF-MSCs led to significant induction of their adipogenic differentiation properties that were altered after miR-26a inhibition. We have demonstrated that miR-26a regulates adipogenesis through direct inhibition of PTEN, which in turn promotes activation of Akt pathway. Also, miR-26a modulates cell cycle during adipogenesis by interacting with Cyclin E1 and CDK6. These results point to the regulatory role of miR-26a and its target genes PTEN, Cyclin E1, and CDK6 in adipogenic differentiation of AF-MSCs, providing a basis for understanding the mechanisms of fat cell development and obesity.
ProckopDJ. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276:71–74.
3.
EnglishK, FrenchA and WoodKJ. (2011). Mesenchymal stromal cells: facilitators of successful transplantation?. Cell Stem Cell, 7:431–442.
4.
De CoppiP, BartschGJr., SiddiquiMM, XuT, SantosCC, PerinL, MostoslavskyG, SerreAC, SnyderEY, et al. (2007). Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol, 25:100–106.
5.
In 't AnkerPS, ScherjonSA, Kleijburg-van der KeurC, NoortWA, ClaasFH, WillemzeR, FibbeWE and KanhaiHH. (2003). Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood, 102:1548–1549.
6.
RoubelakisMG, PappaKI, BitsikaV, ZagouraD, VlahouA, PapadakiHA, AntsaklisA and AnagnouNP. (2007). Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev, 16:931–952.
7.
RoubelakisMG, BitsikaV, ZagouraD, TrohatouO, PappaKI, MakridakisM, AntsaklisA, VlahouA and AnagnouNP. (2011). In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. J Cell Mol Med, 15:1896–1913.
8.
BitsikaV, RoubelakisMG, ZagouraD, TrohatouO, MakridakisM, PappaKI, MariniFC, VlahouA and AnagnouNP. (2012). Human amniotic fluid-derived mesenchymal stem cells as therapeutic vehicles: a novel approach for the treatment of bladder cancer. Stem Cells Dev, 21:1097–1111.
9.
ZagouraDS, TrohatouO, BitsikaV, MakridakisM, PappaKI, VlahouA, RoubelakisMG and AnagnouNP. (2013). AF-MSCs fate can be regulated by culture conditions. Cell Death Dis, 4:e571.
10.
ZagouraDS, RoubelakisMG, BitsikaV, TrohatouO, PappaKI, KapelouzouA, AntsaklisA and AnagnouNP. (2012). Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut, 61:894–906.
11.
JoplingC, BoueS and Izpisua BelmonteJC. (2011). Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nat Rev Mol Cell Biol, 12:79–89.
12.
SinghSK, KagalwalaMN, Parker-ThornburgJ, AdamsH and MajumderS. (2008). REST maintains self-renewal and pluripotency of embryonic stem cells. Nature, 453:223–227.
13.
XuN, PapagiannakopoulosT, PanG, ThomsonJA and KosikKS. (2009). MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell, 137:647–658.
14.
BartelDP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116:281–297.
15.
BartelDP. (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136:215–233.
16.
LakshmipathyU and HartRP. (2008). Concise review: MicroRNA expression in multipotent mesenchymal stromal cells. Stem Cells, 26:356–363.
17.
FoshayKM and GallicanoGI. (2007). Small RNAs, big potential: the role of MicroRNAs in stem cell function. Curr Stem Cell Res Ther, 2:264–271.
18.
TrohatouO, ZagouraD, BitsikaV, PappaKI, AntsaklisA, AnagnouNP and RoubelakisMG. (2014). Sox2 suppression by miR-21 governs human mesenchymal stem cell properties. Stem Cells Transl Med, 3:54–68.
19.
KarbienerM, PisaniDF, FrontiniA, OberreiterLM, LangE, VegiopoulosA, MossenbockK, BernhardtGA, MayrT, et al. (2014). MicroRNA-26 family is required for human adipogenesis and drives characteristics of brown adipocytes. Stem Cells, 32:1578–1590.
AmendolaM, PasseriniL, PucciF, GentnerB, BacchettaR and NaldiniL. (2009). Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther, 17:1039–1052.
22.
ParkH, ParkH, PakHJ, YangDY, KimYH, ChoiWJ, ParkSJ, ChoJA and LeeKW. (2015). miR-34a inhibits differentiation of human adipose tissue-derived stem cells by regulating cell cycle and senescence induction. Differentiation, 90:91–100.
23.
HuseJT, BrennanC, HambardzumyanD, WeeB, PenaJ, RouhanifardSH, Sohn-LeeC, le SageC, AgamiR, TuschlT and HollandEC. (2009). The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev, 23:1327–1337.
24.
ChenJ, CrawfordR, ChenC and XiaoY. (2013). The key regulatory roles of the PI3K/Akt signaling pathway in the functionalities of mesenchymal stem cells and applications in tissue regeneration. Tissue Eng Part B Rev, 19:516–528.
25.
YuW, ChenZ, ZhangJ, ZhangL, KeH, HuangL, PengY, ZhangX, LiS, LahnBT and XiangAP. (2008). Critical role of phosphoinositide 3-kinase cascade in adipogenesis of human mesenchymal stem cells. Mol Cell Biochem, 310:11–18.
26.
BuiTV and MendellJT. (2010). Myc: Maestro of MicroRNAs. Genes Cancer, 1:568–575.
27.
KaurM and ColeMD. (2013). MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase. Cancer Res, 73:695–705.
28.
TropelP, NoelD, PlatetN, LegrandP, BenabidAL and BergerF. (2004). Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. Exp Cell Res, 295:395–406.
29.
ParkH, ChoJA, LimEH, LeeCW, LeeSH, Won SeoS, YangDY and LeeKW. (2011). Cell cycle regulators are critical for maintaining the differentiation potential and immaturity in adipogenesis of adipose-derived stem cells. Differentiation, 82:136–143.
30.
FajasL, FruchartJC and AuwerxJ. (1998). Transcriptional control of adipogenesis. Curr Opin Cell Biol, 10:165–173.
31.
ReichertM and EickD. (1999). Analysis of cell cycle arrest in adipocyte differentiation. Oncogene, 18:459–466.
32.
ZhuY, LuY, ZhangQ, LiuJJ, LiTJ, YangJR, ZengC and ZhuangSM. (2011). MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res, 40:4615–4625.
33.
McGregorRA and ChoiMS. (2011). microRNAs in the regulation of adipogenesis and obesity. Curr Mol Med, 11:304–316.
34.
HeneghanHM, MillerN and KerinMJ. (2010). Role of microRNAs in obesity and the metabolic syndrome. Obes Rev, 11:354–361.
35.
XieH, SunL and LodishHF. (2009). Targeting microRNAs in obesity. Expert Opin Ther Targets, 13:1227–1238.
HamamD, AliD, KassemM, AldahmashA and AlajezNM. (2015). microRNAs as regulators of adipogenic differentiation of mesenchymal stem cells. Stem Cells Dev, 24:417–425.
38.
TrohatouO, AnagnouNP and RoubelakisMG. (2013). Human amniotic fluid stem cells as an attractive tool for clinical applications. Curr Stem Cell Res Ther, 8:125–132.
39.
SongG, XuG, JiC, ShiC, ShenY, ChenL, ZhuL, YangL, ZhaoY and GuoX. (2014). The role of microRNA-26b in human adipocyte differentiation and proliferation. Gene, 533:481–487.
40.
LoweCE, O'RahillyS and RochfordJJ. (2011). Adipogenesis at a glance. J Cell Sci, 124:2681–2686.
41.
FarmerSR. (2006). Transcriptional control of adipocyte formation. Cell Metab, 4:263–273.
42.
KimWK, JungH, KimDH, KimEY, ChungJW, ChoYS, ParkSG, ParkBC, KoY, BaeKH and LeeSC. (2009). Regulation of adipogenic differentiation by LAR tyrosine phosphatase in human mesenchymal stem cells and 3T3-L1 preadipocytes. J Cell Sci, 122:4160–4167.
43.
ZhangHH, HuangJ, DuvelK, BobackB, WuS, SquillaceRM, WuCL and ManningBD. (2009). Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One, 4:e6189.
44.
YehWC, BiererBE and McKnightSL. (1995). Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc Natl Acad Sci U S A, 92:11086–11090.
45.
XuG, JiC, SongG, ZhaoC, ShiC, SongL, ChenL, YangL, HuangF, et al. (2015). MiR-26b modulates insulin sensitivity in adipocytes by interrupting the PTEN/PI3K/AKT pathway. Int J Obes (Lond), 39:1523–1530.
46.
KimJE and ChenJ. (2004). Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes, 53:2748–2756.
47.
YunSJ, KimEK, TuckerDF, KimCD, BirnbaumMJ and BaeSS. (2008). Isoform-specific regulation of adipocyte differentiation by Akt/protein kinase Balpha. Biochem Biophys Res Commun, 371:138–143.
48.
XuJ and LiaoK. (2004). Protein kinase B/AKT 1 plays a pivotal role in insulin-like growth factor-1 receptor signaling induced 3T3-L1 adipocyte differentiation. J Biol Chem, 279:35914–35922.
49.
DeisenrothC, BlackMB, PendseS, PlutaL, WitherspoonSM, McMullenPD and ThomasRS. (2014). MYC is an early response regulator of human adipogenesis in adipose stem cells. PLoS One, 9:e114133.
50.
GuoP, NieQ, LanJ, GeJ, QiuY and MaoQ. (2013). C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. Biochem Biophys Res Commun, 441:186–190.
51.
ChengT. (2004). Cell cycle inhibitors in normal and tumor stem cells. Oncogene, 23:7256–7266.
52.
JakelH, PeschelI, KunzeC, WeinlC and HengstL. (2012). Regulation of p27 (Kip1) by mitogen-induced tyrosine phosphorylation. Cell Cycle, 11:1910–1917.
53.
JanssenHL, ReesinkHW, LawitzEJ, ZeuzemS, Rodriguez-TorresM, PatelK, van der MeerAJ, PatickAK, ChenA, et al. (2013). Treatment of HCV infection by targeting microRNA. N Engl J Med, 368:1685–1694.
54.
BouchieA. (2013). First microRNA mimic enters clinic. Nat Biotechnol, 31:577.
55.
DeiuliisJA. (2016). MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int J Obes (Lond), 40:88–101.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
